Inactive Instrument

Forty Seven, Inc.

Equities

US34983P1049

Biotechnology & Medical Research

Forty Seven, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019

November 12, 2019 at 07:01 am

Forty Seven, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced operating loss was USD 16.373 million compared to USD 22.367 million a year ago. Net loss was USD 15.163 million compared to USD 21.659 million a year ago. Basic loss per share was USD 0.38 compared to USD 0.71 a year ago. For the nine months, operating loss was USD 63.969 million compared to USD 54.321 million a year ago. Net loss was USD 61.385 million compared to USD 53.156 million a year ago. Basic loss per share was USD 1.8 compared to USD 3.63 a year ago.

Latest news about Forty Seven, Inc.

Forty Seven, Inc.(NasdaqGS:FTSV) dropped from S&P TMI Index	20-04-07	CI
Forty Seven, Inc.(NasdaqGS:FTSV) dropped from S&P Global BMI Index	20-04-07	CI
Gilead Sciences, Inc. completed the acquisition of Forty Seven, Inc..	20-04-05	CI
Forty Seven, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-03-20	CI
Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia	20-03-11	CI
Certain Common Stock of Forty Seven, Inc. are subject to a Lock-Up Agreement Ending on 11-MAR-2020.	20-03-10	CI
Certain Stock Options of Forty Seven, Inc. are subject to a Lock-Up Agreement Ending on 11-MAR-2020.	20-03-10	CI
Forty Seven : Thermo Fisher agrees to buy genetic tester Qiagen in $11.5 billion deal	20-03-03	RE
Forty Seven : Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline	20-03-02	RE
Gilead Sciences, Inc. entered into a definitive agreement to acquire Forty Seven, Inc. for $4.6 billion.	20-03-01	CI
Gilead Sciences Reportedly Approaches Forty Seven with a Takeover Offer	20-02-28	CI
Transcript : Forty Seven, Inc. - Special Call	19-12-09
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation	19-12-09	CI
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab	19-12-09	CI
Transcript : Forty Seven, Inc., Q3 2019 Earnings Call, Nov 12, 2019	19-11-12
Forty Seven, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy	19-11-12	CI
Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting	19-11-06	CI
Certain Common Stock of Forty Seven, Inc. are subject to a Lock-Up Agreement Ending on 17-OCT-2019.	19-10-16	CI
Certain Stock Options of Forty Seven, Inc. are subject to a Lock-Up Agreement Ending on 17-OCT-2019.	19-10-16	CI
U.S., Canada and Mexico business leaders say tariffs erode business expansion	19-09-23	RE
Forty Seven, Inc.(NasdaqGS:FTSV) added to S&P Global BMI Index	19-09-23	CI
Transcript : Forty Seven, Inc. Presents at Morgan Stanley 17th Annual Global Healthcare Conference, Sep-10-2019 02:55 PM	19-09-10
Forty Seven, Inc. Receives Fast Track Designation for Magrolimab for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia	19-09-03	CI
Transcript : Forty Seven, Inc., Q2 2019 Earnings Call, Aug 13, 2019	19-08-13

Chart Forty Seven, Inc.

Duration

Period

More charts

Company Profile

Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company's lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company's another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs